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Background: Male patients with chronic kidney disease often exhibit the biological and clinical hallmarks of an
abnormal hypothalamo–pituitary–gonadal axis. It is known that dialysis does not reverse this impaired endocrine
status; however, the impact of kidney transplantation (KT) is still controversial. The aim of our study was to
investigate the levels of serum gonadotropins, testosterone, and inhibin B during dialysis and after KT.
Methods: A longitudinal and prospective single center study was led in an academic setting. Blood hormones levels
were assayed by immunoassays in 53 men (mean age: 37 years) receiving dialysis (T0) and at 6 months post-KT (T180).
These data were compared with those from 46 fertile semen donors (mean age: 37 years). The main outcome measure
was the between-groups differences in hormones levels. A second criterion was the comparison of T0 and T180
hormones levels according to the immunosuppressive regimen.
Results: For patients ongoing dialysis, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) mean
levels were high, whereas testosterone and inhibin B mean levels remained normal. After KT, LH levels returned
to normal whereas FSH was significantly increased. Testosterone levels remained normal whereas inhibin B levels
significantly decreased. We found that the combination tacrolimus plus mycophenolic acid significantly decreased
post-KT inhibin B levels. Moreover, we found that pre-graft inhibin-B level was independent of testosterone and
could predict low post-operative inhibin B level with a sensitivity of 77% and a specificity of 92%.
Conclusions: Our study suggests that endocrine secretions of Leydig and Sertoli cells are differently impacted by
dialysis, KT and immunosuppressive regimen raising new issues to explore.
Keywords: Dialysis, Kidney transplantation, Gonadotropins, Testosterone, Inhibin B, ImmunosuppressionAbstract
Contexte: Les hommes insuffisants rénaux chroniques présentent souvent des signes cliniques et biologiques
d’une atteinte de l’axe hypothalamo-hypophyso-testiculaire. Il est bien établi que la dialyse n’améliore pas ces
anomalies endocriniennes mais l’impact de la transplantation rénale reste encore controversé. Le but de l’étude est
d’explorer les taux circulants des gonadotrophines, de la testostérone et de l’inhibine B durant la période de dialyse
et après la greffe de rein.
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Patients et Méthodes: Cette étude longitudinale et prospective est réalisée dans un centre hospitalo-universitaire.
Les taux sériques des hormones sont mesurés par immunodosage chez 53 patients (âge moyen : 37 ans) durant la
période de dialyse (T0) et 6 mois après la greffe rénale (T180). Ces données sont comparées à celles de 46 donneurs
de sperme fertiles (âge moyen : 37 ans). Le principal critère de jugement est la différence des taux hormonaux entre
les trois groupes. Le critère secondaire est la comparaison des taux pré- et post-greffe en fonction du traitement
immunosuppresseur.
Resultats: Durant la période de dialyse, les taux moyens de LH et de FSH sont élevés alors que ceux de testostérone et
inhibine B sont normaux. Après la greffe, la LH revient à la normale alors que la FSH augmente. Les taux de testostérone
restent normaux mais ceux d’inhibine B augmentent significativement. Par ailleurs, l’étude montre que la combinaison
tacrolimus +mycophénolate diminue clairement les taux post-greffe d’inhibine B. Elle montre également que les taux
pré-greffe d’inhibine B sont indépendants de ceux de la testostérone et qu’ils peuvent prédire les taux bas d’inhibine B
avec une sensibilité de 77% et une spécificité de 92%.
Conclusions: L’étude suggère que les sécrétions endocrines des cellules de Leydig et de Sertoli sont impactées de
manière différente par la dialyse, la transplantation rénale et le traitement immunosuppresseurs ouvrant ainsi de nouvelles
perspectives d’investigation.
Keywords: Dialyse, Transplantation rénale, Gonadotrophines, Testostérone, Inhibine B, ImmunusuppresseursBackground
Abnormalities of the male hypothalamo–pituitary–gonadal
(HPG) axis during end-stage renal disease are well
recognized, including those of testicular function: i.e.,
steroidogenesis and spermatogenesis [1-3]. Unfortunately,
these abnormalities are not reversed in uremic patients
under regular dialysis and can induce hypogonadism, al-
tered spermatogenesis, low libido, erectile dysfunction,
and infertility [4-12]. Moreover, hypogonadism could be
linked to an increased risk of premature cardiovascular
disease and mortality [13,14].
It is now realized that, after a successful KT, hypotha-
lamo–pituitary and testicular dysfunctions may recover,
but the extent of this recovery and the proportion of
grafted patients that do recover is still controversial
[3,10]. It is still not possible to predict the future testicular
function of a uremic patient after a KT.
Inhibin B is a glycoprotein hormone of gonadal origin,
which consists of two dissimilar subunits (α and βB)
linked by a disulfide bond. It is produced by Sertoli cells
in the seminiferous tubules and is the only form of inhibin
present in men. Follicle-stimulating hormone (FSH) is a
potent stimulator of inhibin B production, which, in turn,
regulates FSH in a negative feed-back mechanism. It is
well-established that serum levels of inhibin B are positively
correlated with sperm concentration, total sperm count,
and testicular volume. High serum levels of inhibin B
are observed in normal and fertile individuals whereas
significantly lower serum levels of inhibin B are reported
in men with testicular dysfunction [15]. Thus, inhibin B
has been considered a direct marker for Sertoli-cell
function and an indirect marker for spermatogenesis.
For the above reasons, inhibin B has been used duringthe last two decades to categorize male infertility in
epidemiological studies [16,17]. Recently, inhibin B has
been proposed as a valuable biomarker for human tes-
ticular toxicity [18,19]. In this setting, it would be of
great interest to investigate the serum levels of inhibin
B in men receiving dialysis and/or after a KT, as this
issue has been scarcely addressed in the literature. Our
first objective was to investigate the levels of circulating
pre- and post-KT gonadotropins, testosterone, and inhibin
B in men aged <50 years, and to compare these data with
those from fertile semen donors. Second, we analyzed the
effect of immunosuppressive regimen on testosterone and
inhibin B secretions. Finally, we researched which factors
could predict post-operative inhibin B levels in order to




This longitudinal and prospective study was performed
at the organ-transplant unit of Toulouse University Hos-
pital between May 2006 and March 2008. This study
was approved by the ethics committee of the Universitary
Hospital of Toulouse and written consents were obtained
from all patients or their guardians, as well as from semen
donors. During this period, 257 patients received a KT.
Eligibility criteria are underlined below: of these graft
receivers, 155 were male and, amongst them, 87 were
aged >18 and <50 years. We selected 53 patients whose
blood-hormone assays were available on the day of
transplantation (T0) and at 6 months after (T180). Baseline
clinical data, including age, duration of dialysis, and body-
mass index (BMI), were collected from each patient.
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corticosteroids and were as follows: 19 patients received
tacrolimus (TAC) plus mycophenolic acid (MPA), 18
received cyclosporine A (CsA) plus MPA, nine received
TAC plus the mammalian target of rapamycin (mTORi),
four received belatacept plus MPA, and three patients
received mTORi plus MPA. No specific or additional
treatments were administered to patients for the purpose
of the study and data were collected by reviewing medical
charts.
The control population
The control population consisted of 46 semen donors
recruited from the department of male infertility at
Toulouse University Hospital between December 2006
and May 2011. All donors who gave their informed
consent and had provided a blood sample were included
in the study. The protocols for selecting semen donors
have been reported elsewhere [20]. Briefly, all donors had
previously fathered at least one child and those aged <20
or >45 years, or who had an infertile brother, were
excluded. No specific or additional treatments were
administered to donors for the purpose of the study
and data were collected by reviewing medical charts.
Assessment of blood hormones
Venous blood samples were obtained in the morning
as following: for patients, samples were collected just
before the transplantation (T0) and during the routine
visit of the 6th month post-KT (T180); for semen donors
the blood sample was collected during the routine clinical
examination. Analyses were performed in the clinical
biochemistry department of the hospital. Serum hormone
levels (LH, FSH, total testosterone) were assessed by an
automated immunoassay (Centaur XP of SIEMENS).
For a general population of adult males, the laboratory
reference ranges were 1.5–9.3 IU/L for LH; 1.4–11 IU/L
for FSH, and 288–820 ng/dL for total testosterone. The
inter- and intra-coefficients of variation (CVs) were <3%
for both LH and FSH and, respectively, 4% and 7% for
total testosterone. Serum inhibin B levels were quantified
in duplicate using a manual ELISA protocol from Oxford
Bio Innovation, with a normal range for adult males of
between 80 and 320 pg/mL [21]. The intra- and inter-CVs
were, respectively, 3.5% and 10.2%. The sensitivity of the
assay was set at 15 pg/mL, which was the concentration
that corresponded to the lowest point on the standard
curve. Hence, for the statistics, all serum samples with
an inhibin B concentration of <15 pg/mL were given an
arbitrary value of 14 pg/mL. Since the study was led in
a reproductive endocrinology setting that considers blood
hormones as indirect biomarkers of semen parameters,
their cutoffs were carefully selected. For LH and FSH,
the cutoffs of hypergonadotrophic status were set,respectively, at 8 IU/L [22] and 7 IU/L [23]. Testosterone
deficiency was defined as a total serum testosterone
level <288 ng/dL (<10 nmol/L), in accordance with the
recent international guideline from the Endocrine Society
[24] and the cut-off point for diminished Sertoli-cell
secretion of inhibin B and indirect marker of impaired
spermatogenesis was set at 80 pg/mL [25,26].
Statistical analyses
Comparisons between the groups of patients were per-
formed according to a normality pattern, using the
Kolmogonov–Smirnov test. If the normality test was
positive, the Student’s t-test and a paired t-test were
used for unpaired and paired groups. If the normality
test was negative, the Mann–Whitney and Wilcoxon
rank tests were used. Comparison of several groups
was done using ANOVA, the Holm–Sidak test, and an
ANOVA test of ranks. We used the classification and
regression-tree method [27] to predict the post-KT
inhibin-B levels of our overall data. The number of
missing data is reported in Table 1. Cases and controls
were not matched, an overall comparison was performed.
Statistical significance was set at p <0.05. Statistical ana-
lyses were performed using SigmaStat 3.5 and R packages.
Results
Assessment of blood hormones
In a first approach, we performed overall analyses of the
patients’ and semen donors’ characteristics. Table 1 sum-
marizes their main clinical and biological data as well
as their hormonal status and we report herein some
meaningful results (as mean+/− SD). Semen donors and
graft recipients did not differ in age (36.8 ± 5.3 vs. 37 ±
8 years, respectively, p = 0.73). Prior to a KT, the patients
underwent an average of 35.7 ± 28.6 months of dialysis. At
6 months after transplantation, mean serum creatinine
levels and glomerular-filtration rate (GFR) were 141 ±
79 μmol/L and 57.1 ± 17.2 mL/min, respectively.
Gonadotropins
Before a KT, mean LH level of the KT patients (8.9 IU/L)
slightly exceeded the cutoff and was significantly higher
than the semen donors (3.3 IU/L, p < 0.001). Nineteen
patients (36.5%) had a LH level above the normal range.
Postoperatively, that level decreased significantly (6.7 IU/L,
p < 0.001), but still remained higher than that of the male
controls (3.3 IU/L, p < 0.001). During dialysis, mean FSH
level of the patients (7.7 IU/L) was slightly above the cutoff
and was significantly greater than that of the semen donors
(3.7 IU/L, p = 0.001). Nineteen patients (35.8%) exhibited
abnormally high FSH levels. At 6 months after a KT, FSH
levels had increased significantly (11.3 IU/L, p < 0.001), with
34 patients (65.4%) exhibiting levels above the cutoff.




transplantation (n = 53)
C–graft recipients after
transplantation (n = 53)
p value
B vs A B vs C C vs A
Age (years)a 36.8 (5.3) 37.0 (8.0) – 0.73d
BMIa – 22.6 (4.0) 23.4 (4.1) 0.33
HD duration (months)a – 35.7 (28.6) –
Creatinine (μmol/L)a – 846.0 (221.0) 141.0 (79.0) <0.001
GFR (mL/min)b, LH (IU/L) 57.1 (17.2)
mean, (SD) 3.3 (1.3) 8.9 (6.5) 6.7 (5.0) <0.001 <0.001 <0.001
median, (5th – 95th percentile) 3.1 (1.5–5.8) 6.3 (3.1–24.8) 5.1 (2.0–16.4)
value > 8 UI/Lc, (%) 0 (0.0) 19 (36.5) 13 (24.5)
missing datac, (%) 1 (2.2) 1 (1.9) 0 (0.0)
FSH (IU/L)
mean, (SD) 3.7 (1.7) 7.7 (7.6) 11.3 (8.2) 0.001 <0.001 <0.001
median, (5th–95th percentile) 3.3 (1.4–7.0) 4.9 (1.6–27.5) 9.7 (2.0–29.1)
value > 7 UI/Lc, (%) 1 (2.2) 19 (35.8) 34 (65.4)
missing datac, (%) 1 (2.2) 0 (0.0) 1 (1.9)
Testosterone (ng/dL)
mean (SD) 512 (156) 447 (213) 398 (151) 0.12 0.12 <0.001
median (5th–95th percentile) 522 (261–800) 432 (171–811) 371 (190–618)
value < 288 ng/dLc, (%) 2 (5.2) 12 (22.6) 13 (24.5)
missing datac (%) 8 (17) 5 (9.4) 3 (5.2)
Inhibin B (pg/mL)
mean (SD) 149 (71) 145 (102) 93.6 (79.8) 0.48 <0.001 <0.001
median (5th–95th percentile) 137 (56–309) 127 (14–348) 68 (14–280)
value < 80 pg/mLc, (%) 7 (15.2) 12 (27.9) 25 (47.2)
missing datac, (%) 0 (0.0) 10 (18.9) 8 (15.1)
Data were collected from 46 healthy semen donors and 53 male recipients before (T0) and at 6 months (T180) after a kidney transplant.
aMean (SD), bglomerular filtration rate using the MDRD formula [28], cnumber of events, dstatistical significance is set at p < 0.05.
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Prior to a KT, mean testosterone level of the KT patients
(447 ng/dL) was not significantly different from that of
semen donors (512 ng/dL, p = 0.12). However, the former
were more often hypogonadal (22.6% vs. 5.2%). After
transplantation, the mean testosterone level (398 ng/dL,
p = 0.12) as well as the number of hypogonadal patients
(24.5%) had not significantly changed. Strikingly, the post-
operative mean testosterone level of patients remained
significantly lower than that of donors (p < 0.001).
Inhibin B
Just before a KT, the mean inhibin B level of patients
(145 pg/mL) did not vary from that of semen donors
(149 pg/mL, p = 0.48). By 6 months after a KT, inhibin B
level had significantly decreased (p < 0.001): almost half
of the patients had a serum level <80 pg/mL. Moreover, the
mean inhibin-B level of these graft recipients (93.6 pg/mL)remained siginificantly below that of semen donors
(p < 0.001).
Intra-individual variations in testosterone and inhibin-B
secretions
In a second step, and according to the semiologic value
of testosterone and inhibin B blood concentrations, we
focused on the intra-individual variations before and
after a KT. For both hormones, pre- and post-KT levels
were significantly correlated (Figure 1). However, in a
separate analysis, using linear regression, we found that
inhibin B and testosterone levels before and after a KT
were not correlated (data not shown): this suggests that
both endocrine testicular secretions were independent. By
focusing on the lower limit of testosterone and inhibin B
blood levels (dashed lines), we divided each scatter plot
into four quadrants, each representing a specific subgroup
of patients. We identified those whose hormones levels i)
Figure 1 Linear regression of individual testosterone (panel a, n = 45) and inhibin-B (panel b, n = 36) levels before (T0) and at 6 months
after (T180) transplantation. Dashed lines represent the lower limit of the normal ranges: testosterone, 288 ng/dL; inhibin B, 80 pg/mL. Patients
were then distributed into four subgroups (secretion before/after graft): AT and AI (normal/normal), BT and BI (normal/low), CT and CI (low/low),
and DT and DI (low/normal).
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from normal to low levels (BT, BI); iii) had remained below
the normal ranges (CT, CI); and had recovered to within
the normal range (DT, DI).
Analysis of individual testosterone levels revealed that
60% of patients with a graft remained eugonadal (AT)
whereas 9% remained hypogonadal (CT). The rest of the
patients could be split into two equal groups (15.5%
each): those that had a worsening androgenic status
and had become hypogonadal (BT), and those that had
recovered and had become eugonadal (DT). Overall,
the majority of patients (34 out of 45) were eugonadal
after a KT.
We found a different distribution with regards to
inhibin B levels: 38.8% of patients retained normal hor-
mone levels (AI) whereas 33.3% had levels that were below
the normal range (BI). For the other patients, 25% retained
a low level of inhibin B after transplantation (CI) and only
one patient recovered a normal concentration (DI). Thus,
the majority of KT patients (21 out of 36) exhibited low
inhibin-B levels.
Overall, the patients’ distribution among the four secre-
tion profiles, A, B, C, and D, were not the same for both
hormones. These data suggest that Leydig and Sertoli
cells were differently and independently impacted by
transplantation. In order to confirm this hypothesis, we
focused on the larger subgroup of patients, i.e., those
that remained eugonadal after transplantation (AT). We
found that inhibin B profiles (AI, BI, and CI) were
equally distributed among this subgroup, with, respect-
ively, seven, eight, and seven patients. Despite the small
sizes of the subgroups, we could compare their clinical
and biological data before a KT. There was no difference
in age, duration of dialysis, or testosterone levels between
the three profiles (data not shown). However, mean
inhibin-B levels at T0 did significantly differ withrespectively (±SD): 241 (±89), 135 (±67) and 42 (±25)
pg/mL (p < 0.001). Hence, in the context of preserved tes-
tos-terone secretion, the inhibin B profiles did not rely
on specific features apart from its own initial level. This
finding suggests again an independent impact of KT on
Leydig and Sertoli cells.
Impact of the immunosuppressive regimen on post-KT
testosterone and inhibin B levels
In a third step, we determined the hormonal status of
patients according to their immunosuppressive regimen
(Table 2). We focused on the three main subgroups: CsA
plus MPA (n = 18), TAC plus MPA (n = 19), and TAC plus
mTORi therapy (n = 9). There were no differences in age,
dialysis duration, creatinine, or post-KT GFR between the
three subgroups. Whatever the treatment, the patients
remained eugonadal after a KT, suggesting that these three
regimens did not affect Leydig-cell secretion.
Under the CsA plus MPA therapy, the mean level of
inhibin B did not vary between T0 and T180, remaining
within the normal range (respectively, 172 vs 150 pg/mL,
p = 0.7). For the TAC plus MPA regimen, the mean
inhibin B level before KT was low and decreased sig-
nificantly at post-KT (respectively, 106 and 46.8 pg/mL,
p = 0.026). Under TAC plus mTORi therapy, the mean
inhibin B level diminished from 216 to 99 pg/mL, but
this difference was not significant (p = 0.09).
Prediction of post-operative FSH and inhibin B levels
Finally, we used a regression-tree algorithm to predict
whether post-KT FSH and inhibin-B levels would be
below or above their normal levels, respectively 7 IU/L
and 80 pg/mL. For this purpose, we focused on patients
with a complete set of data (n = 36). Regarding FSH, we
found that the unique predictive variable was pre-KT
FSH level, and that its cutoff value was 9.6 IU/L, with a
Table 2 Clinical, biological, and hormonal data of patients at T0 and T180 according to immunosuppressive regimen
CsA +MPA (n = 18) TAC +MPA (n = 19) TAC +mTORi (n = 9)
T0 T180 T0 T180 T0 T180
Age (years)a 36.6 (5.3) 37.6 (8.5) 36.6 (7.9)
Time on dialysis (months) 35.1 (27.3) 36.4 (27.4) 42.0 (38.6)
Creatinin (μmol/L) 822 (223) 844 (209) 854 (167)
GFR (mL/min)b 56.3 (15.0) 52.5 (19.8) 67.1 (17.8)
Testosterone (ng/dL) 493 (205) 392 (92) 415 (212) 380 (181) 465 (272) 445 (129)
p-value (T0 vs. T180) 0.118
c 0.605c 0.845c
Inhibin B (pg/mL) 172 (72) 150 (158) 106 (85) 46.8 (50.0) 216 (140) 99.4 (57.5)
p-value (T0 vs. T180) 0.703
c 0.026d 0.093d
aMean (SD), busing the MDRD formula [28], cpaired Student’s t-test, dMann–Whitney test.
Hamdi et al. Basic and Clinical Andrology 2014, 24:11 Page 6 of 9
http://www.bacandrology.com/content/24/1/11specificity of 70% and a sensitivity of 100% (Figure 2).
For inhibin B, the unique predictive variable was its own
pre-KT level with a cutoff value of 128 pg/mL. The
sensitivity was lower (77%) than that of FSH but the spe-
cificity was higher (92%). This means that a patient with an
inhibin B level of <128 pg/mL before transplantation, what-
ever his age, hormonal status, or immunosuppressive treat-
ment, had a relatively high risk of developing low post-
KT levels.Discussion
It is now known that, after a successful KT, hypotha-
lamo–pituitary and testicular dysfunctions can recover,
but the extent of this recovery and the proportion of grafted
patients that do fully recover is still controversial [3,10].
It is still not possible to predict if the future testicular
functions of a uremic patient will be affected after a KT.Figure 2 Regression-tree analysis. a, FSH. A cutoff of 9.6 IU/L at T0
can predict post-transplantation levels with a sensitivity of 100% and
a specificity of 70%. b, inhibin B. A cutoff of 128 pg/mL at T0 can
predict post-transplantation levels with a sensitivity of 77% and a
specificity of 92%.In our report, we have explored the hormonal status
of 53 patients under dialysis and just prior to a KT. The
mean level of testosterone in dialyzed patients was not
significantly different from that of the male controls;
however, 23% of our patients were within the hypogonadal
range, a finding that is consistent with the LH results
(Table 1).
Several previous studies have reported that mean testos-
terone level in dialysis patients was normal or “suboptimal”
[5,7,9,11,12], whereas the percentages of hypogonadal pa-
tients varied from 37 to 80%. This discrepancy between
studies may result from the small numbers of patients as
well as from their ambiguous definition of hypogonadism.
For our study, we categorized a man as hypogonadal if his
testosterone level was <288 ng/dL (10 nmol/L), which
is in accordance with a recent international guideline
from the Endocrine Society [24]. The common condition
of hypogonadism in dialysis patients, which may be
primary or secondary [3], has been linked to several
clinical features, such as reduced libido, erectile dys-
function [6,8,10,12,29], and low ejaculate volume [7,12].
With regards to inhibin B, we found that median serum
levels did not significantly differ between semen donors
and dialysis patients. This result seems conflicting with
that of FSH levels which were higher in the latter group.
However, the standard deviation was higher in dialysis
patients, indicating that some subjects exhibited very low
levels of inhibin B and the lack of significant difference
between the means could be due to the missing data in
this group (10/53 for inhibin B levels versus 0/53 for
FSH levels, Table 1).
In a further step, we analyzed the impact of the kidney
graft on the HPG axis. LH levels decreased significantly
whereas those of FSH increased and exceeded the cutoff.
Mean testosterone levels did not significantly differ before
and after a KT, and the proportion of hypogonadal
patients remained stable (25% vs 23%). However, we
observed a noteworthy decrease in inhibin B secretion
in 47% of graft recipients who had hormone levels
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with the increase in FSH after a KT, as reported above.
Many studies have described the evolution of the HPG
axis before and after a kidney graft [7,9,11,12], and have
reported global recovery, but this comparison is difficult
to confirm because of the heterogeneity of data (mainly:
number and age of patients, dialysis duration, duration of
follow-up, hormone assays, and, if detailed, immunosup-
pressive regimen).
In a last step, we compared patients who had received a
graft with control semen donors (Table 1, III vs. I column).
Obviously, the four hormone levels were significantly dif-
ferent between the two groups. This indicates that, in the
setting of our study, the HPG axis had not fully recovered
by 6 months after the KT. The global variation in HPG
axis hormones (reported above) hides the fact that a var-
iety of individual patterns can be aggregated into specific
categories. This issue has been scarcely addressed in the
literature: only two reports have differentiated patients
according to their testosterone levels before a KT [10,11].
In the present report, we first compared pre- and post-
KT testosterone levels and identified four secretion profiles
(Figure 1). Overall, the patients remained eugonadal after
a KT (75%). Moreover, their androgenic status after a
KT depended only on preoperative testosterone levels
(data not shown). Regarding inhibin B, we identified
four profiles (AI, BI, CI, DI), which were not distributed
between the patients in the same way as those of testos-
terone. The majority of patients exhibited a low inhibin
B level after a KT and only one recovered a normal level.
We surmise from these results that both testosterone and
inhibin B secretions were independently impacted by the
KT. Two additional findings support this hypothesis.
There were no correlations between the two hormone
levels (data not shown) and, when we explored the indi-
vidual variations of inhibin B, we found that profiles AI,
BI, CI were equally distributed within the eugonadal group
AT. Thus, even in the setting of normal testosterone secre-
tion (AT), Sertoli cells could react differently at post-KT.
We then compared the effect of immunosuppressive
regimens on testis hormones (Table 2). Both calcineurin
inhibitors (CsA and TAC), coupled to MPA, did not
impair testosterone secretion, a finding that is consistent
with previous studies [30,5]. However, their effect on
inhibin-B secretion was different: the mean inhibin B
level under CsA plus MPA remained normal whereas
it was significantly decreased under TAC plus MPA.
Of interest, one study reports that TAC induces mor-
phological alterations of seminiferous tubules and re-
duces the number of Sertoli cells in rats [31]. However,
it is tricky to assess with certainty whether TAC plus
MPA are involved in the decreased inhibin-B levels, as
the mean preoperative level of this hormone was
already low.It has been previously reported that sirolimus may im-
pair testicular function [32,33] and male heart transplant
recipients treated with sirolimus exhibited a significant
increase in FSH levels and a drop of testosterone level
[34]. In our study, the TAC plus mTORi regimen did not
affect testosterone levels, but reduced those of inhibin B
although the decrease was not significant (p = 0.093) (with
the small number of patients within the subgroup as an
acceptable reason). These findings further suggest that
the immunosuppressive regimens differently impacted
on Leydig and Sertoli cells.
After the study, we wondered whether it was possible to
identify predictive variables for post-KT FSH and inhibin
B levels. Using regression-tree algorithms, we found that
cut-off levels of 9.6 IU/L and 128 pg/mL for FSH and in-
hibin B, respectively, could predict for abnormal post-KT
levels. The specificity of inhibin B cut-off was higher than
that of FSH (Figure 2) and may be more helpful to predict
testicular impairment. Of interest, this level is still within
the normal range (80–320 pg/mL). Because it is well
known that dialysis patients have poor semen quality and
fertility [35-39] such a normal value is quite puzzling.
However, one can assume that uremic patients exhibit, as
they do for gonadotropins, reduced metabolic clearance of
inhibin B, and that serum levels of this hormone could be
artificially high as they are decoupled from spermatogen-
esis status. Such an interesting hypothesis deserves further
investigation.
Despite some positive features, such as the number of
included patients, the cross-sectional design, and the use
of semen donors as the controls, our study has some
limitations. The study is monocentric, the hormonal as-
sessments were made at only 6 months after a KT, and
the clinical significance of the variations in testosterone
and inhibin B, such as sexual function, spermatogenesis, or
fertility, were not assessed. However, this study confirms
the controversial status of the HPG recovery after a KT and
the need for large, multicentric, prospective, and long-term
studies.
Conclusions
The mains findings of our study are the following: recov-
ery from abnormal testicular function, as observed during
hemodialysis, was incomplete at 6 months after a KT; dia-
lysis, KT or immunosuppressive regimen did not impact
Leydig and Sertoli cells to the same extent. It also high-
lights the significance of testosterone and inhibin B assays
in this setting and raises new issues into managing the
fertility of male transplant patients.
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